Menopause and the Mirror: The Unspoken Toll on Skin and Self

ZUG, Switzerland – January 30, 2026 – For millions of women, the onset of menopause brings a cascade of changes, many of which remain shrouded in a surprising degree of silence. A new global survey has cast a harsh light on one of the most visible yet least discussed aspects: the profound transformation of the skin. The findings, unveiled by dermatology leader Galderma at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, reveal a significant "knowledge gap," with over half of women learning about menopause-related skin effects only as they were happening.

This widespread lack of forewarning has left many feeling unprepared and distressed by changes that impact not just their appearance, but their confidence and quality of life. In response, Galderma has announced a two-pronged initiative aimed at shattering the silence: a commitment to education and a pioneering decision to formally include menopausal status in all its future clinical trials for injectable aesthetics, a move that could set a new industry standard.

The Hidden Toll of Hormonal Shifts

The survey, which polled over 4,300 peri- and post-menopausal women across nine countries, paints a stark picture of a shared but unspoken experience. On average, women reported experiencing three distinct skin changes to their face and body. The most common complaints were an increase in lines and wrinkles (59%), a loss of firmness and elasticity (58%), and pervasive dryness (56%).

These are not minor cosmetic concerns. The psychological and emotional impact is substantial, with 60% of respondents agreeing that the changes made them feel less attractive. The effects ripple outward, with 57% feeling more anxious, 55% reporting a drop in confidence, and nearly half (46%) admitting they wanted to socialize less. The overall severity of these changes was rated a six out of ten by participants.

The science behind this transformation is well-documented but not widely understood by the public. The menopausal transition is marked by a steep decline in estrogen, a hormone crucial for maintaining skin health. Within the first five years after menopause, the skin can lose up to 30% of its collagen, the protein that provides structural support and firmness. This collagen crash, coupled with a reduction in naturally occurring hyaluronic acid that keeps skin hydrated, directly leads to the sagging, thinning, and dryness that so many women in the survey reported. The problem, the data suggests, is that this crucial information isn't reaching women early enough. Over 30% of those surveyed wished they had learned about these effects in their 30s, and more than 60% said they would have acted differently with earlier knowledge.

A New Benchmark for an Overlooked Demographic

Addressing this gap between scientific understanding and public awareness is at the heart of Galderma's new strategy. The company has made the groundbreaking decision to systematically include and analyze menopausal status in all its future clinical trials for injectable aesthetic treatments. This move is a direct acknowledgment that women navigating this life stage have unique physiological needs that have been historically overlooked in dermatological research.

While women make up the vast majority of aesthetic patients—around 85%—many clinical studies fail to specifically analyze data based on menopausal status or the use of hormone replacement therapy. This omission creates a significant blind spot, making it difficult to develop truly evidence-based treatment protocols for this demographic. The company’s commitment aims to change that, providing robust data on how its treatments perform in women experiencing these specific hormonal shifts.

"As the pure-play dermatology category leader, we are committed to driving meaningful change for every skin story," said Bill Andriopoulos, Ph.D., Head of Global Medical Affairs at Galderma. "Through this global survey, close collaboration with our network of experts and ensuring that menopausal status is included in all our clinical trials moving forward, we aim to elevate awareness and advance aesthetic solutions, backed by robust evidence, for women navigating this important life stage."

This initiative is poised to challenge the broader aesthetics industry, potentially pressuring competitors to adopt similar inclusive research practices and move beyond a one-size-fits-all approach to treating aging skin.

Bridging the Gap with Science-Backed Solutions

While education is a critical first step, the survey also highlighted a strong interest in effective interventions. Among all actions taken to mitigate the effects of menopause—including behavioral therapy, exercise, and supplements—aesthetic treatments garnered the highest level of satisfaction. This indicates a growing recognition that targeted dermatological procedures can effectively address the underlying biological changes in the skin.

"Aesthetic treatments are important tools in addressing and preventing the varied menopause-related skin changes women can experience," commented Dr. Doris Day, a board-certified dermatologist from the United States. "Hyaluronic acid treatments can help to correct skin changes through enhanced hydration and contour, whereas biostimulators can help to regenerate skin health from the inside by boosting collagen and elastin to improve firmness and radiance."

The survey data reflects a significant openness to these options. Nearly half of the women (47%) would consider anti-wrinkle treatments, while 41% would consider hyaluronic acid fillers. Biostimulators, which work to regenerate the skin's own collagen supply, are being considered by 30% of respondents. Products like Galderma's Sculptra®, a biostimulator, and its Restylane® portfolio of hyaluronic acid fillers are designed to directly counteract the loss of collagen and hydration that defines menopausal skin.

However, the knowledge gap has a direct impact on treatment timing. Currently, women primarily use these treatments for correction (49%) rather than prevention (26%). With earlier education, women could potentially take a more proactive approach, addressing skin quality changes before they become more pronounced.

The Burgeoning Menopause Market

Galderma's focus on menopause is not just a scientific imperative; it is also a savvy response to a massive and rapidly growing market. The global menopause market, valued at nearly $18 billion in 2024, is projected to exceed $24 billion by 2030. The "menopause beauty" segment alone is a multi-billion-dollar industry, reflecting a powerful demographic that is tired of being ignored and is actively seeking effective, evidence-backed solutions.

For years, the wellness and beauty industries have been criticized for focusing on longevity models built around male biology. This is shifting, as a growing movement demands greater attention to female healthspan, with menopause at its center. This demographic has significant economic power and is increasingly unwilling to accept vague marketing claims. The demand is for products and treatments backed by rigorous science tailored to their specific needs.

By embedding menopausal status into its clinical research, the dermatology leader is positioning itself at the forefront of this evolution. The initiative not only promises to deliver more effective treatments but also builds trust with a consumer base that values transparency and scientific validation. This strategic pivot could catalyze a broader industry trend, compelling other companies to invest in more inclusive research and product development, ultimately leading to better care and more empowering choices for women worldwide.